T cell recognition of beryllium

Current Opinion in Immunology

Volumn 25, Issue 6, 2013, Pages 775-780

  Dai, Shaodong ^a   Falta, Michael T ^b   Bowerman, Natalie A ^b   McKee, Amy S ^b   Fontenot, Andrew P ^a,b  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERYLLIUM; GLUTAMIC ACID; HLA ANTIGEN; HLA DP2 ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ALLELE; AMINO ACID SEQUENCE; BETA CHAIN; BINDING SITE; CD4+ T LYMPHOCYTE; CHRONIC BERYLLIUM DISEASE; DISEASE ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; LUNG DISEASE; NONHUMAN; PROTEIN STRUCTURE; REVIEW; T LYMPHOCYTE;

BERYLLIOSIS; BERYLLIUM; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS;

EID: 84889081427     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.07.012     Document Type: Review

References (46)

1. Yin L., Crawford F., Marrack P., Kappler J.W., Dai S. T-cell receptor (TCR) interaction with peptides that mimic nickel offers insight into nickel contact allergy. Proc Natl Acad Sci U S A 2012, 109:18517-18522.
2. Kreiss K., Newman L.S., Mroz M., Campbell P.A. Screening blood test identifies subclinical beryllium disease. J Occup Med 1989, 31:603-608.
3. Kreiss K., Wasserman S., Mroz M.M., Newman L.S. Beryllium disease screening in the ceramics industry: blood test performance and exposure-disease relations. J Occup Med 1993, 35:267-274.
4. Kreiss K., Mroz M.M., Zhen B., Martyny J.W., Newman L.S. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis 1993, 148:985-991.
5. 3. Am J Ind Med 1996, 30:16-25.
6. Henneberger P.K., Cumro D., Deubner D.D., Kent M.S., McCawley M., Kreiss K. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 2001, 74:167-176.
7. Newman L.S., Mroz M.M., Balkissoon R., Maier L.A. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 2004, 171:54-60.
8. Newman L.S., Kreiss K., King T.E., Seay S., Campbell P.A. Pathologic and immunologic alterations in early stages of beryllium disease: re-examination of disease definition and natural history. Am Rev Respir Dis 1989, 139:1479-1486.
9. Newman L.S., Kreiss K. Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferation response to beryllium. Am Rev Respir Dis 1992, 145:1212-1214.
10. Newman L.S., Rose C.S., Maier L.A. Sarcoidosis. N Engl J Med 1997, 336:1224-1234.
11. Jones-Williams W., Kelland D. New aid for diagnosing chronic beryllium disease (CBD): laser ion mass analysis (LIMA). J Clin Pathol 1986, 39:900-901.
12. Jones-Williams W., Wallach E.R. Laser microprobe mass spectrometry (LAMMS) analysis of beryllium, sarcoidosis, and other granulomatous diseases. Sarcoidosis 1989, 6:111-117.
13. Newman L.S., Lloyd J., Daniloff E. The natural history of beryllium sensitization and chronic beryllium disease. Environ Health Perspect 1996, 104:937S-943S.
14. + T cells in patients with chronic beryllium disease. J Clin Invest 2002, 110:1473-1482.
15. Tinkle S.S., Kittle L.A., Schumacher B.A., Newman L.S. Beryllium induces IL-2 and IFN-γ in berylliosis. J Immunol 1997, 158:518-526.
16. Fontenot A.P., Falta M.T., Freed B.M., Newman L.S., Kotzin B.L. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J Immunol 1999, 163:1019-1026.
17. + T cells in blood determines proliferative response. J Clin Invest 2005, 115:2886-2893.
18. + T cells. J Clin Invest 2003, 112:776-784.
19. Saltini C., Winestock K., Kirby M., Pinkston P., Crystal R.G. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989, 320:1103-1109.
20. Richeldi L., Sorrentino R., Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993, 262:242-244.
21. Richeldi L., Kreiss K., Mroz M.M., Zhen B., Tartoni P., Saltini C. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med 1997, 32:337-340.
22. Wang Z., White P.S., Petrovic M., Tatum O.L., Newman L.S., Maier L.A., Marrone B.L. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol 1999, 163:1647-1653.
23. Rossman M.D., Stubbs J., Lee C.W., Argyris E., Magira E., Monos D. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med 2002, 165:788-794.
24. Maier L.A., McGrath D.S., Sato H., Lympany P., Welsh K., Du Bois R., Silveira L., Fontenot A.P., Sawyer R.T., Wilcox E., et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol 2003, 171:6910-6918.
25. McCanlies E.C., Ensey J.S., Schuler C.R., Kreiss K., Weston A. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization. Am J Ind Med 2004, 46:95-103.
26. Silveira L.J., McCanlies E.C., Fingerlin T.E., Van Dyke M.V., Mroz M.M., Strand M., Fontenot A.P., Bowerman N., Dabelea D.M., Schuler C.R., et al. Chronic beryllium disease, HLA-DPB1, and the DP peptide binding groove. J Immunol 2012, 189:4014-4023.
27. Rosenman K.D., Rossman M., Hertzberg V., Reilly M.J., Rice C., Kanterakis E., Monos D. HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity. Occup Environ Med 2011, 68:487-493.
28. Dai S., Murphy G.A., Crawford F., Mack D.G., Falta M.T., Marrack P., Kappler J.W., Fontenot A.P. Crystal structure of HLA-DP2: Implications for chronic beryllium disease. Proc Natl Acad Sci U S A 2010, 107:7425-7430.
29. Painter C.A., Cruz A., Lopez G.E., Stern L.J., Zavala-Ruiz Z. Model for the peptide-free conformation of class II MHC proteins. PLoS ONE 2008, 3:e2403.
30. Fremont D.H., Dai S., Chiang H., Crawford F., Marrack P., Kappler J. Structural basis of cytochrome c presentation by IE(k). J Exp Med 2002, 195:1043-1052.
31. Latek R.R., Suri A., Petzold S.J., Nelson C.A., Kanagawa O., Unanue E.R., Fremont D.H. Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. Immunity 2000, 12:699-710.
32. - complex with phosphoserine phosphatase. Proc Natl Acad Sci U S A 2001, 98:8525-8530.
33. + T cells underlies disease susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci U S A 2000, 97:12717-12722.
34. Lombardi G., Germain C., Uren J., Fiorillo M.T., du Bois R.M., Jones-Williams W., Saltini C., Sorrentino R., Lechler R. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J Immunol 2001, 166:3549-3555.
35. Gilchrist F.C., Bunce M., Lympany P.A., Welsh K.I., du Bois R.M. Comprehensive HLA-DP typing using polymerase chain reaction with sequence-specific primers and 95 sequence-specific primer mixes. Tissue Antigens 1998, 51:51-61.
36. + T cells is dependent on a single amino acid residue of the MHC class II β-chain. J Immunol 2005, 175:7029-7037.
37. Sethi D.K., Schubert D.A., Anders A.K., Heroux A., Bonsor D.A., Thomas C.P., Sundberg E.J., Pyrdol J., Wucherpfennig K.W. A highly tilted binding mode by a self-reactive T cell receptor results in altered engagement of peptide and MHC. J Exp Med 2011, 208:91-102.
38. Hahn M., Nicholson M.J., Pyrdol J., Wucherpfennig K.W. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat Immunol 2005, 6:490-496.
39. Li Y., Huang Y., Lue J., Quandt J.A., Martin R., Mariuzza R.A. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J 2005, 24:2968-2979.
40. Bowerman N.A., Falta M.T., Mack D.G., Kappler J.W., Fontenot A.P. Mutagenesis of beryllium-specific TCRs suggests an unusual binding topology for antigen recognition. J Immunol 2011, 187:3694-3703.
41. Diaz G., Canas B., Vazquez J., Nombela C., Arroyo J. Characterization of natural peptide ligands from HLA-DP2: new insights into HLA-DP peptide-binding motifs. Immunogenetics 2005, 56:754-759.
42. Falta M.T., Pinilla C., Mack D.G., Tinega A., Crawford F., Guilianotti M., Santos R., Clayton G.M., Wang Y., Zhang X., et al. Identification of peptides recognized by CD4 T cells in chronic beryllium disease. J Exp Med 2013, 210:1403-1418.
43. Sidney J., Steen A., Moore C., Ngo S., Chung J., Peters B., Sette A. Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity. J Immunol 2010, 184:2492-2503.
44. Roney K., Holl E., Ting J. Immune plexins and semaphorins: old proteins, new immune functions. Protein Cell 2013, 4:17-26.
45. Marrack P., Kappler J.W. Do MHCII-presented neoantigens drive type 1 diabetes and other autoimmune diseases?. Cold Spring Harb Perspect Med 2012, 2:2-17.
46. Illing P.T., Vivian J.P., Dudek N.L., Kostenko L., Chen Z., Bharadwaj M., Miles J.J., Kjer-Nielsen L., Gras S., Williamson N.A., et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012, 486:554-558.